martes, 24 de febrero de 2026
In 2026, drug discovery faces a higher bar Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
https://www.drugdiscoverynews.com/in-2026-drug-discovery-faces-a-higher-bar-16997?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8yAVWjuXEKY32ZcNe9QydBmgJyTL4i8znpMLbjAOaQQRcBp_f_YKgfxwUnDKXf9PRoeB49U712rocMUeu57uhUykhIeg&_hsmi=405284917&utm_content=405284917&utm_source=hs_email
After several years of contraction, biopharma is heading into 2026 with measurable signs of recovery. The Nasdaq Biotechnology Index reached a record high in late 2025, large pharmaceutical companies committed more than $36 billion to biotech acquisitions in just two months, and late-stage clinical successes have begun translating into higher valuations.
Blockbuster drugs face a massive patent cliff in 2026 Generic and biosimilar competition is poised to disrupt billions in annual drug sales, reshaping market dynamics for some of the industry’s most important medicines.
https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8FpRA_clew71NPJmVat5rbxixpCI0Md-EB1dhkQKKfSzev0alK-lbF0ggSI-7uEbMWJsrU5qONEcy5mH3ES7wCMiNMQ&_hsmi=405284917&utm_content=405284917&utm_source=hs_email
In the world of pharmaceuticals, patents matter. They grant drugmakers exclusive rights to sell a medicine for a defined period, allowing companies to recover massive research and development costs and, in many cases, generate profits to fund future innovation. Once those patents expire, however, the competitive landscape shifts dramatically as cheaper generic or biosimilar versions can enter the market, often leading to steep price reductions and sharply reduced revenue for the original brand.
Florida, Trump Administration At Odds Over Medicaid Program Application
Florida, Trump Administration At Odds Over Medicaid Program Application
Florida’s Republican congressional delegation is getting involved in an effort to get approval for the program, which boosts payments to state hospitals. Also: AbbVie is planning two manufacturing facilities in North Chicago; Camp Mystic parents sue the state of Texas; and more.
https://kffhealthnews.org/morning-breakout/florida-trump-administration-at-odds-over-medicaid-program-application/
On Trump’s Request, High Court Agrees To Hear Case On Fossil Fuel Lawsuits
On Trump’s Request, High Court Agrees To Hear Case On Fossil Fuel Lawsuits
In an unusual move, the Trump administration asked the Supreme Court to take up the case of whether or not states and cities can sue large oil and gas companies for climate change damages driven by greenhouse gas emissions and pollution from the industry.
https://kffhealthnews.org/morning-breakout/on-trumps-request-high-court-agrees-to-hear-case-on-fossil-fuel-lawsuits/
Dentists Keep Prescribing Clindamycin Despite ‘Black Box’ Label, C Diff Risk
Dentists Keep Prescribing Clindamycin Despite ‘Black Box’ Label, C Diff Risk
CIDRAP takes a deeper look at the antibiotic's health effects. Also in the news: The FDA has approved milsaperidone to treat schizophrenia and bipolar disorder; Bayer sues Johnson & Johnson; Mounjaro may reduce alcohol intake; and more.
https://kffhealthnews.org/morning-breakout/dentists-keep-prescribing-clindamycin-despite-black-box-label-c-diff-risk/
Kaiser Mental Health Therapists Vote To Strike Just As Nurses Are Returning
Kaiser Mental Health Therapists Vote To Strike Just As Nurses Are Returning
A day after the union representing more than 31,000 Kaiser Permanente health care professionals noted productive labor negotiations and agreed to end the four-week walkout, KP mental health therapists in California voted to authorize a one-day unfair labor practice strike.
https://kffhealthnews.org/morning-breakout/kaiser-mental-health-therapists-vote-to-strike-just-as-nurses-are-returning/
Suscribirse a:
Comentarios (Atom)

